IDEXX Laboratories, Inc. vs Valero Energy Corporation — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while Valero Energy Corporation trades at $433.75 (market cap $127.78B). The key difference: Valero Energy Corporation is far larger — about 3.2× IDEXX Laboratories, Inc.'s market cap, and Valero Energy Corporation pays a 1.08% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Valero Energy Corporation for 56 Days on average.
| IDXX | VLO | |
|---|---|---|
Market Cap | $40.43B | $127.78B |
Volume | 692,164 | 2,570,225 |
Sector | Health | Energy |
52-Week High | $766.68 | $443.80 |
52-Week Low | $504.70 | $156.39 |
Typical Hold Time | 46 Days | 56 Days |
Enterprise Value | $41.32B | $131.26B |
Dividend Yield | — | 1.08% |
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $513.14, up 1.28% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $4.27 exceeding the $3.94 estimate. Revenue grew to $4.3 billion in 2025, and net income margin expanded to 25.03%. Recent acquisitions like CoVetAI aim to enhance veterinary workflow intelligence.
The outlook remains positive given robust profitability and analyst consensus, but risks include foreign exchange headwinds and competitive pressures. With a consensus price target of $665, representing ~30% upside, the stock offers growth potential for investors comfortable with its premium valuation multiples.
Valero Energy (VLO) trades at $443.80, up 4.65% with strong bullish momentum near its 52-week high. The stock shows robust technical strength with moving averages in bullish alignment, though RSI indicates overbought conditions. Fundamentally, VLO has beaten earnings estimates for three consecutive quarters with Q3 2026 expectations at $20.41 EPS. Revenue declined to $122.69B in 2025 but is projected to recover to $139.4B in 2026, while maintaining strong profitability metrics including 29.31% ROE.
VLO presents a compelling growth story with refining margins supporting cash flow generation, though current valuation at 18.51 P/E appears fair. Key risks include potential diesel export restrictions and cyclical energy demand. Analyst consensus remains bullish with 54% buy ratings and $408.10 price target, though current price exceeds consensus. The stock's Gulf Coast advantage and strong balance sheet provide fundamental support for continued outperformance.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →Valero Energy is one of the largest independent refiners in the United States. It operates 14 refineries with a total throughput capacity of 3.2 million barrels a day in the United States, Canada, and the United Kingdom. Valero also owns 14 ethanol plants with capacity of 1.7 billion gallons of ethanol a year and holds a 50% stake in Diamond Green Diesel, which has capacity to produce 700 million gallons per year of renewable diesel.
Read more on VLO →